The Chikujee NanoBindi technology adapted for RNAi is called NanoRISC™. NanoRISC overcomes the significant hurdles for the delivery of RNAi therapeutics allowing for efficient, targeted and/or systemic delivery of siRNA. Chikujee has demonstrated that the technology has the following features that are readily adaptable to RNAi-based drug molecules as well.

1. Allows for repeat dosing without the risk of immune reactions

2. Has demonstrated efficient, targeted delivery in animal models

3. Has overcome the extra- and intra-cellular barriers to siRNA delivery

4. Has been scaled-up and manufactured for clinical use

The technology, called NanoRISC™ is a designed nanoparticle therapeutics that:

¨      Greatly enhance solublization of low solubility molecules

¨      Provide for long circulation in humans (half life of ca. 40 hours) by designed modulation of absorption, distribution, metabolism and excretion

¨      Target specific disease tissues

¨      Have controlled and tunable drug release profiles to match mechanism of action